BioAge Labs (BIOA) Income from Continuing Operations (2023 - 2026)
BioAge Labs (BIOA) reported Income from Continuing Operations of 22207000.0 for Q1 2026, down 70.4% on a YoY basis from 75032829.66 in Q1 2025, and down 42.98% sequentially from 15531000.0 in Q4 2025.
BioAge Labs (BIOA) Income from Continuing Operations (2023 - 2026) Analysis & Trends
BioAge Labs (BIOA) has 4 years of Income from Continuing Operations data on file, last reported at 22207000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 70.4% year-over-year to 22207000.0; the trailing twelve-month figure through Mar 2026 stood at 91848000.0 (up 35.39% YoY), and the FY2025 full-year result was 125940000.0, down 56.33% from the prior year.
- Income from Continuing Operations declined to 22207000.0 in Q1 2026, from 15531000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 11791000.0 in Q3 2023 to a low of 82204000.0 in Q3 2024.
- A 4-year average of 25468727.27 and a median of 20324000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations slumped 597.18% in 2024 and surged 65.27% in 2025, its largest moves.
- Tracing BIOA's Income from Continuing Operations over 4 years: stood at 20324000.0 in 2023, then tumbled by 53.59% to 31215000.0 in 2024, then jumped by 50.25% to 15531000.0 in 2025, then slumped by 42.98% to 22207000.0 in 2026.
- Business Quant data shows BIOA's Income from Continuing Operations at 22207000.0 in Q1 2026, 15531000.0 in Q4 2025, and 28553000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | BioAge Labs | 930.32 Mn | 930.32 Mn | -10.37 Mn | -22.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.21 Mn |
| Dec 31, 2025 | -15.53 Mn |
| Sep 30, 2025 | -28.55 Mn |
| Jun 30, 2025 | -25.56 Mn |
| Mar 31, 2025 | -13.03 Mn |
| Dec 31, 2024 | -31.22 Mn |
| Sep 30, 2024 | -82.20 Mn |
| Jun 30, 2024 | -15.71 Mn |
| Mar 31, 2024 | -14.03 Mn |
| Dec 31, 2023 | -20.32 Mn |
| Sep 30, 2023 | -11.79 Mn |